nivolumab
bms
[]
#asco22 pcr does need to be validated and we need good surrogates (as well as os outcomes). many other differences between neoadjuvant and adjuvant strategies - advantages of each mean we need to tailor our approach to the specific situation. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him